NattoPharma, CARIM enter longterm R&D agreement

By Maggie Hennessy

- Last updated on GMT

NattoPharma, supplier of MenaQ7 vitamin K2 ingredients, has inked long-term research agreement with the Cardiovascular Research Institute Maastricht, (CARIM), and University of Maastricht, Netherlands, enabling NattoPharma to evaluate new vitamin K2 technologies, create proof of concept studies for novel delivery systems and evaluate the impact of vitamin K2 on human health.

The agreement comes on the heels of a grant from the Dutch government to investigate effects of vitamin K supplementation on cardiovascular disease in patient and volunteer serum/plasma reflected by a biohybrid platform based on human vascular smooth muscle cells.

“This achievement confirms the success of NattoPharma's strategy to secure a substantial part of our product development and innovation project costs through public funding, grants and in collaboration with high-level scientific institutions," ​said Frode M. Bohan, chairman of the board of NattoPharma, in a statement.

NattoPharma already works with VitaK at the University of Maastricht. This collaboration resulted in the recently published three-year study demonstrating bone health and bone strength benefits of MenaQ7 Vitamin K2 in healthy post-menopausal women in Osteoporosis International​. The new agreement with CARIM complements and expands NattoPharma’s R&D efforts.

Related topics Suppliers

Related news

Follow us

Products

View more

Webinars